WorldCat Identities

Deconinck, Eric

Overview
Works: 23 works in 28 publications in 2 languages and 260 library holdings
Roles: Author, Thesis advisor, Other, Contributor, Opponent
Classifications: RC643, 616.994
Publication Timeline
.
Most widely held works by Eric Deconinck
Blastic plasmacytoid dendritic cell neoplasm by Eric Deconinck( )

1 edition published in 2021 in English and held by 212 WorldCat member libraries worldwide

Fast Facts: Blastic Plasmacytoid Dendritic Cell Neoplasm : Shedding light on a rare disease by Eric Deconinck( )

3 editions published in 2021 in English and held by 10 WorldCat member libraries worldwide

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare fast-growing hematodermic neoplasm that most often occurs in older men. It is notable for its highly aggressive behavior, with cutaneous, lymph node and bone marrow involvement. In the past, BPDCN has been poorly understood, recognized and treated, and consequently has had a poor prognosis. Today, it has been reclassified as a myeloid neoplasm and there is greater understanding of the disease's clinical features, course and pathology, a new diagnostic test that makes prompt diagnosis possible and a new targeted therapy that, so far, has been shown to at least double survival. The complexity of caring for patients with BPDCN stems from both its rarity and its multiorgan involvement. 'Fast Facts: Blastic Plasmacytoid Dendritic Cell Neoplasm' is designed to bring hematologists, oncologists, dermatologists, pathologists, clinical nurse specialists and trainees in all these fields up to speed on the latest developments, as well as providing the most up-to-date information on first-line chemotherapy, consolidation treatments and stem cell transplantation. It will aid readers of all relevant medical disciplines to implement prompt diagnosis and effective management. Table of Contents: • What is BPDCN? Diagnosis • Management • Unmet needs and future directions
L'intensification thérapeutique dans le traitement des hémopathies lymphoïdes et des formes sévères de maladies autoimmunes : quelle place à l'heure des explorations génomiques et des thérapies moléculaires ciblées ? by Éric Deconinck( )

2 editions published in 2003 in French and held by 3 WorldCat member libraries worldwide

L'intensification thérapeutique dans le traitement des hémopathies lymphoides et des formes sévères de maladies autoimmunes Quelle place à / 'heure des explorations génomiques et des thérapies moléculaires ciblées? Deux études évaluent l'autogreffe purgée, en première ligne de traitement des lymphomes folliculaires. Deux autres études évaluent le potentiel curateur de l'autogreffe pour les lymphomes anaplasiques à grandes cellules. Les aspects pharmacoéconomiques de l'utilisation des 2 G-CSF disponibles pour le recueil de cellules en vue d'autogreffe au cours des hémopathies lymphoïdes sont évalués au cours d'une étude randomisée. Parallèlement l'impact de la richesse du greffon sur l'évolution post-autogreffe des lymphomes "malins de haut gade de malignité a été analysée. L'autogreffe avec conditionnement myéloablateur est testée chez 4 patients atteints de formes sévères de sclérose en plaques dans une étude rétrospective locale et européenne. Nous apportons des éléments en faveur de l'autogreffe en première ligne pour les lymphomes de haut grade mais pas pour ceux de bas grade et nous précisons la place de l'autogreffe dans le traitement scléroses en plaques sévères
Donor selection for a second allogeneic stem cell transplantation in AML patients relapsing after a first transplant: a study of the acute leukemia working party of EBMT by Avichai Shimoni( )

2 editions published in 2019 in English and held by 3 WorldCat member libraries worldwide

Abstract: Second allogeneic stem-cell transplantation (SCT2) is a therapeutic option for patients with AML relapsing after a first transplant. Prior studies have shown similar results after SCT2 from the same or different donor; however, there are limited data on second non-T-depleted haplo-identical transplant in this setting. We retrospectively analyzed SCT2 outcomes in 556 patients, median age 46 years, relapsing after first transplant given in CR1. Patients were divided into three groups based on SCT2 donor (donor2): same donor (n = 163, sib/sib-112, UD/UD-51), different matched donor (n = 305, sib/different sib-44, sib/UD-93, UD/different UD-168), or haplo-donor (n = 88, sib/haplo-45, UD/haplo-43). Two-year leukemia-free survival (LFS) rate after SCT2 was 23.5%, 23.7%, and 21.8%, respectively (P = 0.30). Multivariate analysis showed no effect of donor2 type on relapse: hazard ratio (HR) 0.89 (P = 0.57) and 1.11 (P = 0.68) for different donor and haplo-donor compared to same donor, respectively. However, donor2 did predict for non-relapse mortality (NRM) after SCT2: HR 1.21 (P = 0.50) and 2.08 (P = 0.03), respectively, and for LFS: HR 1.00 (P = 0.97) and 1.43 (P = 0.07), respectively. In conclusion, SCT2 with the same or different matched donor is associated with similar outcomes in patients with relapsed AML. Non-T-depleted haplo-identical transplant may be associated with higher NRM, similar relapse rate and with no better results in this setting
New CD20 alternative splice variants: molecular identification and differential expression within hematological B cell malignancies by Clémentine Gamonet( )

1 edition published in 2016 in English and held by 2 WorldCat member libraries worldwide

Complete remission after first-line radio-chemotherapy as predictor of survival in extranodal NK/T cell lymphoma by Adrien Chauchet( )

1 edition published in 2012 in English and held by 2 WorldCat member libraries worldwide

SYNDROMES LYMPHOPROLIFERATIFS ASSOCIES AU VIRUS D'EPSTEIN-BARR CHEZ DES SUJETS IMMUNOCOMPETENTS : A PROPOS DE TROIS OBSERVATIONS ET REVUE DE LA LITTERATURE by JEAN FONTAN( Book )

1 edition published in 1996 in French and held by 2 WorldCat member libraries worldwide

Cost Effectiveness of Rituximab Maintenance Therapy in Follicular Lymphoma Long-Term Economic Evaluation by Eric Deconinck( )

1 edition published in 2010 in English and held by 2 WorldCat member libraries worldwide

Erratum to: New CD20 alternative splice variants: molecular identification and differential expression within hematological B cell malignancies by Clémentine Gamonet( )

1 edition published in 2016 in English and held by 2 WorldCat member libraries worldwide

The quality coefficient as performance assessment parameter of straight line calibration curves in relationship with the number of calibration points by Jacques O. De Beer( )

1 edition published in 2012 in English and held by 2 WorldCat member libraries worldwide

SECONDE ALLOGREFFE DE MOELLE OSSEUSE POUR RECHUTE D'HEMOPATHIE MALIGNE : A PROPOS DE 5 OBSERVATIONS by Éric Deconinck( Book )

1 edition published in 1990 in French and held by 2 WorldCat member libraries worldwide

Development of a quantitative PCR detecting Cunninghamella bertholletiae to help in diagnosing this rare and aggressive mucormycosis by Anne-Pauline Bellanger( )

1 edition published in 2018 in English and held by 2 WorldCat member libraries worldwide

Identification de nouveaux transcrits alternatifs du gène CD20 humain, différentiellement exprimés dans les hémopathies impliquant le lymphocyte B by Clémentine Gamonet( Book )

2 editions published in 2015 in French and held by 2 WorldCat member libraries worldwide

La protéine D393-CD20, codée par un transcrit alternatif du gène cd20 découvert au laboratoire en 2010, est expriméedans les lymphocytes B (LB) tumoraux et surexprimée lors de résistance et rechute aux traitements par Rituximab(Henry et al, Blood 2010). Lors de nos travaux, cinq variants alternatifs de cd20, homologues à la séquence sauvage mais délétés d'une portioninterne, ont été identifiés par séquençage à partir de LB tumoraux. En plus de D393-CD20, 4 nouveaux variantsexistent : D657-, D618-, D480- et D177-CD20. Les variants D657- et D618-CD20 sont faiblement exprimés dans les LB de donneurs sains et surexprimés lors de lasurvenue de pathologies impliquant les LB, alors que D393-CD20 n'est exprimé que dans les LB tumoraux. L'étude par PCR quantitative du profil d'épissage de patients atteints de pathologies B ainsi que chez des donneurssains, a révélé une dérégulation de l'épissage de cd20 lors de la survenue de pathologies impliquant le LB. L'expression spécifique aux LB tumoraux de D393-CD20 suggère une dérégulation spécifique de l'épissage lors de lasurvenue de cancers, particulièrement au niveau des centres germinatifs. Si nos modèles in vitro de résistance démontrent que la présence de D393-CD20 n'est pas directement associée à larésistance aux AcMo, nous avons montré que ces derniers peuvent moduler l'épissage de cd20 par l'intermédiaire devoies de signalisation intra cellulaires. Ces résultats ouvrent donc la voie à une étude plus approfondie du potentiel biomarqueur et du rôle pronostique de la dérégulation de l'épissage du gène codant CD20, cible prépondérante des stratégies thérapeutiques des pathologies impliquant le lymphocyte B
Lymphome folliculaire transformé : apport de l'intensification thérapeutique avec autogreffe de cellules souches hématopoïétiques by Katell Le Dû( Book )

1 edition published in 2005 in French and held by 2 WorldCat member libraries worldwide

La transformation histologique fait partie de l'évolution du lymphome folliculaire avec une incidence de 20 à 70% des cas. Le pronostic est sombre avec une survie globale inférieure à un an avec le traitement de chimiothérapie conventionnelle. D'autres perspectives thérapeutiques ont été évaluées et notamment l'intensification thérapeutique. - Dans le Service d'hématologie du CHU de Besançon, 22 patients ont été autogreffés de 1992 à 2003 pour un lymphome folliculaire transformé. Le taux de réponse global est de 62% avec un recul médian de 39 mois. La survie globale estimée à 2 ans et 5 ans est de 90% et 60% respectivement. La mortalité liée à la greffe est de 9% avec une incidence de myélodysplasie secondaire de 4,5%. Le taux de rechute de cette série est de 33%. - L'intensification thérapeutique permet d'obtenir une survie prolongée avec une incidence de rechute qui reste élevée. La toxicité liée à la greffe restreint l'indication de greffe aux patients jeunes et répondeurs
Evaluation médico-économique de deux formes de G-CSF dans les autogreffes pour hémopathies lymphoïdes by Bruno Mandy( Book )

1 edition published in 2002 in French and held by 1 WorldCat member library worldwide

Nationwide survey on the use of horse antithymocyte globulins (ATGAM) in patients with acquired aplastic anemia: A report on behalf of the French Reference Center for Aplastic Anemia( )

1 edition published in 2018 in English and held by 1 WorldCat member library worldwide

Abstract: Antithymocyte globulins (ATG) plus cyclosporine (CSA) is the gold standard immunosuppressive treatment (IST) for patients with aplastic anemia. A prospective randomized trial showed in 2011 that hATG was superior to rabbit ATG for first-line treatment of severe AA. The French Health Agency (ANSM) permitted a patient-named authorization for temporary use (ATU) program of hATG (ATGAM, Pfizer) in patients with AA in 2011 since commercial access to hATG is not approved. We took advantage of this program to analyze the outcomes of 465 patients who received antithymocyte globulins (ATGAM) plus CSA as first line treatment (n = 379; 81.5%), or for refractory (n = 26) or relapsed disease (n = 33), from September 2011 to March 2017. In the entire cohort one year, 72% of the patients had partial and 13% had complete response, with worse response for patients with severe AA and a longer interval between diagnosis and IST (more than 6 months). Severe adverse events were mainly linked to infections (24%), hemorrhages (6%), and elevated liver function tests (5%). Overall at 12 months, 9.7% of patients required second line IST and 15.6% received transplantation. Fifty-five patients died during the study mainly because of infections (53%). Factors predicting independently worse survival were age over 40 years, neutrophils less than 0.5 × 10 9 /L, male gender and longer delay between diagnosis and hATG (>6 months period). This study does illustrate the results of ATGAM with CSA in a true-life perspective and confirms ATGAM as standard of care IST to treat patients with AA not eligible for HSCT
Immune stimulation during chemotherapy increases incidence of acute graft versus host disease in acute myeloid leukemia: A study on behalf of SFGM-TC and ALFA( )

1 edition published in 2017 in English and held by 1 WorldCat member library worldwide

Highlights: Cutaneous immune stimulation during induction increases the incidence of skin aGVHD. Digestive immune stimulation during induction increases the incidence of gut aGVHD. Prolonged febrile duration correlates with elevated incidence of grade II-IV aGvHD. Identification of a group of patients with higher risk of aGvHD. Abstract: 60-70% of AML patients have an indication of allogeneic hematopoietic stem cell transplantation (allo-HSCT) during their treatment. Graft versus host disease (GvHD), the major cause of mortality and comorbidities post-transplantation, develops by immunological mechanism and decides greatly prognosis and quality of life (QoL) of graft recipient. Current GvHD prophylaxis is not personalized. Infections, toxicities and leukemic infiltration complicate the first chemotherapy phases prior to allo-HSCT. They, to certain extent, induce local immune stimulation. Impact of immune stimulation of this period on incidence of GvHD has not been evaluated. We retrospectively studied 238 AML patients transplanted at first remission from 21 French centers in the ALFA-0702 protocol and found that cutaneous and digestive immune stimulation during induction increases the incidence of skin and gut aGVHD, respectively. Furthermore, prolonged febrile duration correlates with elevated incidence of grade II-IV aGvHD. Thus, we identified a group of patients with higher risk of aGvHD. The benefit of personalized GvHD prophylaxis should be explored in a prospective cohort to decrease incidence of aGvHD in these patients and improve their QoLs
 
moreShow More Titles
fewerShow Fewer Titles
Audience Level
0
Audience Level
1
  General Special  
Audience level: 0.00 (from 0.00 for Blastic pl ... to 0.00 for Blastic pl ...)

Blastic plasmacytoid dendritic cell neoplasm Fast Facts: Blastic Plasmacytoid Dendritic Cell Neoplasm : Shedding light on a rare disease
Covers
Fast Facts: Blastic Plasmacytoid Dendritic Cell Neoplasm : Shedding light on a rare disease
Languages
English (16)

French (9)